2023 |
Mohammed, H., Pham-Tran, D. D., Yeoh, Z. Y. M., Wang, B., McMillan, M., Andraweera, P. H., & Marshall, H. S. (2023). A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). Vaccines, 11(2), 19 pages. DOI Scopus3 WoS2 Europe PMC2 |
2023 |
Wang, B., Andraweera, P., Elliott, S., Mohammed, H., Lassi, Z., Twigger, A., . . . Marshall, H. S. (2023). Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis. Pediatric Infectious Disease Journal, 42(3), 232-239. DOI Scopus5 WoS4 Europe PMC5 |
2023 |
Wang, B., Giles, L., Andraweera, P., McMillan, M., Almond, S., Beazley, R., . . . Marshall, H. (2023). 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post program implementation. Journal of Infection, 87(2), 95-102. DOI |
2023 |
Andraweera, P. H., Wang, B., Danchin, M., Blyth, C., Vlaev, I., Ong, J., . . . Marshall, H. S. (2023). Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccines among pregnant women (the EPIC study): study protocol. Trials, 24(1), 454-1-454-8. DOI |
2023 |
Wang, B., & Marshall, H. S. (2023). A new era for equity in meningococcal disease prevention. The Lancet Infectious Diseases, S1473-3099(23)00232-3. DOI |
2022 |
Wang, B., Giles, L., Andraweera, P., McMillan, M., Almond, S., Beazley, R., . . . Marshall, H. (2022). Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. The Lancet Infectious Diseases, 22(7), 1011-1020. DOI Scopus24 WoS19 Europe PMC9 |
2022 |
Wang, B., Nolan, R., Krumeich, B., D'Onise, K., & Marshall, H. (2022). COVID-19 vaccine willingness prior to and during the COVID-19 vaccination rollout in Australia. Human Vaccines and Immunotherapeutics, 18(5), 2079345-1-2079345-9. DOI Scopus3 WoS2 Europe PMC2 |
2021 |
Marshall, H. S., Andraweera, P. H., Wang, B., McMillan, M., Koehler, A. P., Lally, N., . . . Flood, L. (2021). Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol. Human Vaccines and Immunotherapeutics, 17(5), 1450-1454. DOI Scopus8 WoS7 Europe PMC4 |
2021 |
McMillan, M., Wang, B., Koehler, A. P., Sullivan, T. R., & Marshall, H. S. (2021). Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents.. Clin Infect Dis, 73(1), e233-e237. DOI Scopus15 WoS10 Europe PMC5 |
2021 |
Wang, B., Nolan, R., & Marshall, H. (2021). Covid-19 immunisation, willingness to be vaccinated and vaccination strategies to improve vaccine uptake in Australia. Vaccines, 9(12), 1467. DOI Scopus6 WoS6 Europe PMC6 |
2020 |
Marshall, H. S., Koehler, A. P., Wang, B., A'Houre, M., Gold, M., Quinn, H., . . . Macartney, K. (2020). Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia. Vaccine, 38(37), 5914-5922. DOI Scopus8 WoS6 Europe PMC1 |
2019 |
Wang, B., Santoreneos, R., Giles, L., Haji Ali Afzali, H., & Marshall, H. (2019). Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine, 37(21), 2768-2782. DOI Scopus103 WoS93 Europe PMC54 |
2019 |
Wang, B., Hajiali Afzali, H., Giles, L., & Marshall, H. (2019). Lifetime costs of invasive meningococcal disease: a Markov model approach. Vaccine, 37(46), 6885-6893. DOI Scopus4 WoS2 Europe PMC4 |
2019 |
Marshall, H., McMillan, M., Wang, B., Booy, R., Afzali, H., Buttery, J., . . . Barton, B. (2019). AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.. BMJ Open, 9(12), e032583. DOI Scopus3 WoS3 Europe PMC2 |
2018 |
Wang, B., Santoreneos, R., Afzali, H., Giles, L., & Marshall, H. (2018). Costs of invasive meningococcal disease: a global systematic review. PharmacoEconomics, 36(10), 1201-1222. DOI Scopus18 WoS15 Europe PMC12 |
2017 |
Wang, B., Chen, G., Ratcliffe, J., Afzali, H., Giles, L., & Marshall, H. (2017). Adolescent values for immunisation programs in Australia: a discrete choice experiment. PLoS ONE, 12(7), e0181073-1-e0181073-14. DOI Scopus16 WoS15 Europe PMC13 |
2016 |
Marshall, H., Wang, B., Wesselingh, S., Snape, M., & Pollard, A. J. (2016). Control of invasive meningococcal disease: Is it achievable?. International Journal of Evidence-Based Healthcare, 14(1), 3-12. DOI Scopus9 WoS9 Europe PMC3 |
2016 |
Wang, B., Giles, L., Afzali, H., Clarke, M., Ratcliffe, J., Chen, G., & Marshall, H. (2016). Adolescent confidence in immunisation: assessing and comparing attitudes of adolescents and adults. Vaccine, 34(46), 5595-5603. DOI Scopus13 WoS12 Europe PMC8 |
2014 |
Wang, B., Clarke, M., Hajiali Afzali, H., & Marshall, H. (2014). Community, parental and adolescent awareness and knowledge of meningococcal disease. Vaccine, 32(18), 2042-2049. DOI Scopus21 WoS18 Europe PMC16 |
2014 |
Wang, B., Clarke, M., Thomas, N., Howell, S., Afzali, H., & Marshall, H. (2014). The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatric Infectious Disease Journal, 33(3), 316-318. DOI Scopus21 WoS24 Europe PMC12 |
2014 |
Wang, B., Haji Ali Afzali, H., & Marshall, H. (2014). The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine, 32(37), 4791-4798. DOI Scopus29 WoS23 Europe PMC18 |